Regarding patients with HER2-negative, estrogen receptor (ER)-positive breast cancer, the phase 3 KEYNOTE-756 study is ...

T-DM1 reduced risk of invasive disease events and death compared with trastuzumab in HER2-positive early breast cancer with ...

It is not known if Kadcyla increases the length of time people live because the final trial results are not yet available. The decision comes a few months after European regulators approved ...

Kadcyla (trastuzumab emtansine) is Roche's 'next generation' version of its hugely successful breast cancer drug Herceptin for people with HER2 positive breast cancer.

We are working with Guy’s and St. Thomas’ NHS Foundation Trust to produce national standardised SACT regimen-specific consent forms. We want to support clinicians in ensuring all patients are fully ...

Kadcyla and Perjeta, the new class of drugs launched in India in October, cost Rs 2,10,000 (200 ml) and Rs 2,49,000 for a dosage, respectively. ET verified the price with several chemists and ...